3H-spiperone binding sites in post-mortem brains from schizophrenic patients: Relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms
- 68 Downloads
In post-mortem putamen samples from 27 schizophrenics and 27 controls D2 receptors were measured by Scatchard analysis using3H-spiperone as a ligand. Maximum number of binding sites (Bmax) and apparent dissociation constant (KD) were significantly increased only in patients in whom neuroleptic medication had been given within a three-month period before death. When the neuroleptic medication had been withdrawn at least 3 month before death, there was a slight, but not significant, reduction in Bmax values and unchanged KD values. Withdrawal of neuroleptic drugs was followed by a normalization of the KD values within 2 weeks and a slower reduction of Bmax values. There were 6 schizophrenic patients with mainly positive schizophrenic symptoms and 17 patients with mainly negative symptoms; positive schizophrenic symptoms were not related to higher Bmax values. There was no difference in3H-spiperone binding between patients with and without movement disorders (tardive dyskinesia or extrapyramidal symptoms).
KeywordsD2 receptor schizophrenia spiperone tardive dyskinesia neuroleptic drugs
Unable to display preview. Download preview PDF.
- Crawley JCW, Crow TJ, Johnstone EC, Oldland SRD, Owen F, Owens DGC, Smith T, Veall N, Zanelli GD (1986) Uptake of77Br-spiperone in the striata of schizophrenic patients and controls. Nuclear Med Commun 7: 599–607Google Scholar
- Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Johnstone EC, Owen F, Owens DGC, Poulter M (1985) Chemical and structural changes in the brain in patients with movement disorders. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia: research and treatment. Springer Verlag, Berlin Heidelberg New York Tokyo, pp 104–110Google Scholar
- Crow TJ, Owen F, Cross AJ, Ferrier N, Johnstone EC, McCreadie RM, Owens DGC, Poulter M (1981) Neurotransmitter enzymes and receptors in post-mortem brain in schizophrenia: evidence that an increase in D2 dopamine receptors is associated with the Type I Syndrome. In: Riederer P, Usdin E (eds) Transmitter biochemistry of human brain tissue. Macmillan, London, pp 85–96Google Scholar
- Fibiger HC, Lloyed KG (1984) Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci 12: 462–464Google Scholar
- Herold S, Leenders KL, Turton DR, Kensett MJ, Pike VW, Clark JC, Brooks DJ, Crow TJ, Owen F, Cooper S, Johnstone EC (1985) Dopamine receptor binding in schizophrenic patients as measured with11C-methylspiperone and PET. J Cereb Blood Flow Metab 5: S 191-S 192Google Scholar
- Owen F, Cross AJ, Crow TJ, Longden A, Poulter M, Riley GJ (1978) Increased dopaminereceptor sensitivity in schizophrenia. Lancet II: 223–226Google Scholar
- Reynolds GP, Reynolds LM, Riederer P, Jellinger K, Gabriel E (1980) Dopamine receptors and schizophrenia: drug effect or illness? Lancet II: 1251Google Scholar
- Toru M, Nishikawa T, Semba J, Mataga N, Takashima M, Noda K, Shibuya H (1982) Increased dopamine metabolism in the putamen and caudate in schizophrenic patients. In: Namba M, Kaiya H (eds) Psychobiology of schizophrenia. Pergamon Press, Oxford, pp 235–240Google Scholar
- Wong DF, Wagner HN, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung JKT, Malat J, Williams JA, O'Tuama LA, Snyder SH, Kuhar MJ, Gjedde A (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234: 1558–1563PubMedGoogle Scholar